Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsShortsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Jack Kain, PharmD

Advertisement

Articles by Jack Kain, PharmD

Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

ByJack Kain, PharmD
June 16th 2022

Although the CDC has put forth a strong effort to improve its opioid guidelines, many providers still feel that more can be done.

Advertisement

Latest Updated Articles

  • Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?
    Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

    June 16th 2022



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer: What Nurses Need to Know

2

FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumors

3

FDA Approves Gedatolisib for HR+/HER2- Metastatic Breast Cancer

4

Managing Oncology Care Amidst Rising Wildfire Smoke and Poor Air Quality

5

Optimizing Multiple Myeloma Care: Insights From a Nursing Expert

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us